| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 13 | 2022 | 647 | 2.330 |
Why?
|
| Streptococcus agalactiae | 10 | 2022 | 26 | 1.900 |
Why?
|
| Placenta | 7 | 2022 | 101 | 1.370 |
Why?
|
| Chorioamnionitis | 4 | 2022 | 40 | 1.130 |
Why?
|
| Streptococcal Infections | 8 | 2022 | 53 | 1.030 |
Why?
|
| Anemia | 3 | 2022 | 104 | 1.010 |
Why?
|
| Folic Acid | 6 | 2022 | 123 | 1.010 |
Why?
|
| Inflammasomes | 2 | 2019 | 39 | 0.830 |
Why?
|
| Decidua | 2 | 2020 | 8 | 0.830 |
Why?
|
| Pregnancy | 21 | 2023 | 2334 | 0.820 |
Why?
|
| Global Health | 1 | 2022 | 136 | 0.780 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 92 | 0.720 |
Why?
|
| Palmitic Acid | 1 | 2019 | 51 | 0.690 |
Why?
|
| Folic Acid Deficiency | 2 | 2018 | 16 | 0.680 |
Why?
|
| Clostridium sordellii | 2 | 2022 | 4 | 0.660 |
Why?
|
| Prostaglandins E | 1 | 2018 | 54 | 0.640 |
Why?
|
| Reproduction | 1 | 2018 | 48 | 0.630 |
Why?
|
| Clostridium Infections | 2 | 2019 | 52 | 0.580 |
Why?
|
| Escherichia coli | 1 | 2018 | 368 | 0.540 |
Why?
|
| Premature Birth | 4 | 2022 | 150 | 0.520 |
Why?
|
| Iron | 4 | 2022 | 197 | 0.500 |
Why?
|
| Cytokines | 8 | 2022 | 866 | 0.500 |
Why?
|
| Apoptosis | 3 | 2019 | 1641 | 0.490 |
Why?
|
| Immunity, Innate | 6 | 2021 | 156 | 0.470 |
Why?
|
| Extracellular Traps | 3 | 2018 | 9 | 0.460 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2013 | 2 | 0.450 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 12 | 0.450 |
Why?
|
| Hemoglobins | 3 | 2022 | 120 | 0.450 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2003 | 17 | 0.430 |
Why?
|
| Female | 38 | 2023 | 38074 | 0.420 |
Why?
|
| Prevalence | 7 | 2022 | 1619 | 0.420 |
Why?
|
| Inflammation | 4 | 2020 | 1030 | 0.410 |
Why?
|
| Vitamin A Deficiency | 3 | 2021 | 11 | 0.390 |
Why?
|
| Dietary Supplements | 5 | 2022 | 332 | 0.390 |
Why?
|
| Humans | 46 | 2023 | 68618 | 0.360 |
Why?
|
| Immune Tolerance | 4 | 2021 | 114 | 0.350 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2022 | 34 | 0.340 |
Why?
|
| Dinoprostone | 3 | 2015 | 110 | 0.340 |
Why?
|
| Intestinal Mucosa | 3 | 2019 | 219 | 0.330 |
Why?
|
| Extraembryonic Membranes | 2 | 2020 | 10 | 0.330 |
Why?
|
| Neural Tube Defects | 3 | 2018 | 27 | 0.320 |
Why?
|
| Vitamin A | 2 | 2021 | 111 | 0.320 |
Why?
|
| Food, Fortified | 3 | 2017 | 38 | 0.300 |
Why?
|
| Phagocytosis | 3 | 2018 | 65 | 0.300 |
Why?
|
| Micronutrients | 2 | 2020 | 31 | 0.280 |
Why?
|
| Methylmalonic Acid | 2 | 2003 | 6 | 0.270 |
Why?
|
| Vitamin B 12 | 2 | 2003 | 21 | 0.270 |
Why?
|
| Homocysteine | 2 | 2003 | 28 | 0.270 |
Why?
|
| Monocytes | 2 | 2017 | 210 | 0.270 |
Why?
|
| Mice | 14 | 2022 | 8474 | 0.270 |
Why?
|
| Escherichia coli Infections | 2 | 2018 | 47 | 0.260 |
Why?
|
| Fullerenes | 4 | 2007 | 18 | 0.250 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2005 | 72 | 0.250 |
Why?
|
| Cell Line | 4 | 2018 | 1752 | 0.250 |
Why?
|
| World Health Organization | 4 | 2023 | 53 | 0.250 |
Why?
|
| Animals | 19 | 2022 | 20881 | 0.240 |
Why?
|
| Guidelines as Topic | 3 | 2015 | 123 | 0.240 |
Why?
|
| Amnion | 2 | 2020 | 15 | 0.230 |
Why?
|
| Lactoferrin | 2 | 2021 | 6 | 0.230 |
Why?
|
| Milk, Human | 2 | 2021 | 147 | 0.230 |
Why?
|
| Infant, Newborn | 8 | 2023 | 2455 | 0.220 |
Why?
|
| Puerperal Infection | 2 | 2013 | 15 | 0.220 |
Why?
|
| Fetal Membranes, Premature Rupture | 2 | 2020 | 45 | 0.220 |
Why?
|
| Streptococcus | 2 | 2020 | 15 | 0.220 |
Why?
|
| Maternal Health Services | 1 | 2023 | 22 | 0.210 |
Why?
|
| Helicobacter Infections | 1 | 2003 | 40 | 0.210 |
Why?
|
| Helicobacter pylori | 1 | 2003 | 54 | 0.210 |
Why?
|
| Dendritic Cells | 3 | 2010 | 201 | 0.200 |
Why?
|
| Psoas Abscess | 1 | 2022 | 1 | 0.200 |
Why?
|
| Metalloporphyrins | 3 | 2007 | 25 | 0.200 |
Why?
|
| Child | 6 | 2022 | 6405 | 0.200 |
Why?
|
| Bacterial Capsules | 1 | 2021 | 8 | 0.200 |
Why?
|
| Shock, Septic | 1 | 2022 | 101 | 0.190 |
Why?
|
| Trophoblasts | 2 | 2020 | 29 | 0.190 |
Why?
|
| Insulin | 2 | 2019 | 619 | 0.190 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 22 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 529 | 0.190 |
Why?
|
| Epoprostenol | 1 | 2021 | 71 | 0.190 |
Why?
|
| Bayes Theorem | 1 | 2022 | 307 | 0.180 |
Why?
|
| Stromal Cells | 1 | 2020 | 113 | 0.180 |
Why?
|
| Adult | 11 | 2022 | 21403 | 0.180 |
Why?
|
| Cell Communication | 1 | 2020 | 116 | 0.170 |
Why?
|
| Self-Management | 1 | 2021 | 82 | 0.170 |
Why?
|
| Lipopolysaccharides | 3 | 2018 | 455 | 0.170 |
Why?
|
| Bacteremia | 1 | 2022 | 155 | 0.170 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 189 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 199 | 0.170 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2020 | 46 | 0.170 |
Why?
|
| Diet | 1 | 2003 | 514 | 0.170 |
Why?
|
| Respiratory Burst | 1 | 2018 | 6 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 17 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 1026 | 0.160 |
Why?
|
| Embryo Implantation | 1 | 2018 | 17 | 0.160 |
Why?
|
| Paracrine Communication | 1 | 2018 | 31 | 0.160 |
Why?
|
| Indomethacin | 1 | 2019 | 107 | 0.160 |
Why?
|
| Young Adult | 6 | 2022 | 5717 | 0.160 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 2550 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2021 | 2689 | 0.160 |
Why?
|
| Biomarkers | 3 | 2017 | 1593 | 0.150 |
Why?
|
| Glucose | 1 | 2019 | 307 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2020 | 431 | 0.150 |
Why?
|
| Chorionic Villi | 1 | 2017 | 5 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 157 | 0.150 |
Why?
|
| Protein Kinase C | 1 | 2019 | 270 | 0.150 |
Why?
|
| Reproductive Tract Infections | 1 | 2017 | 3 | 0.140 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 35 | 0.140 |
Why?
|
| Prenatal Care | 3 | 2023 | 117 | 0.140 |
Why?
|
| Asthma | 1 | 2021 | 345 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 122 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 63 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2017 | 66 | 0.140 |
Why?
|
| Phagosomes | 1 | 2016 | 19 | 0.140 |
Why?
|
| Misoprostol | 1 | 2016 | 6 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 69 | 0.140 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2016 | 8 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 240 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 2016 | 64 | 0.140 |
Why?
|
| Pericytes | 1 | 2017 | 81 | 0.140 |
Why?
|
| Vagina | 1 | 2016 | 88 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 186 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 186 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 156 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 226 | 0.130 |
Why?
|
| Nutritional Status | 2 | 2017 | 112 | 0.130 |
Why?
|
| Biofilms | 3 | 2021 | 72 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2016 | 215 | 0.120 |
Why?
|
| Adolescent | 4 | 2022 | 8912 | 0.120 |
Why?
|
| THP-1 Cells | 3 | 2020 | 7 | 0.120 |
Why?
|
| Erythrocytes | 1 | 2015 | 137 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 468 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2008 | 300 | 0.120 |
Why?
|
| HIV-1 | 2 | 2012 | 177 | 0.110 |
Why?
|
| SEER Program | 1 | 2014 | 153 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2017 | 310 | 0.110 |
Why?
|
| Transcobalamins | 2 | 2003 | 2 | 0.110 |
Why?
|
| Guatemala | 2 | 2003 | 9 | 0.110 |
Why?
|
| Leukotriene B4 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2013 | 682 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 93 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 2013 | 223 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2013 | 246 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2017 | 902 | 0.100 |
Why?
|
| Minority Groups | 1 | 2014 | 197 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2010 | 17 | 0.100 |
Why?
|
| Imidazoles | 2 | 2003 | 175 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2022 | 3187 | 0.100 |
Why?
|
| Iodine | 1 | 2011 | 42 | 0.100 |
Why?
|
| Viremia | 1 | 2010 | 13 | 0.090 |
Why?
|
| Virulence | 2 | 2022 | 51 | 0.090 |
Why?
|
| Middle Aged | 5 | 2022 | 21147 | 0.090 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Interleukin-23 | 1 | 2010 | 13 | 0.090 |
Why?
|
| Immunity, Mucosal | 1 | 2010 | 19 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2003 | 1040 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2019 | 2673 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 378 | 0.090 |
Why?
|
| DNA | 2 | 2017 | 597 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 592 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2010 | 57 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 174 | 0.090 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 101 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 848 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2010 | 233 | 0.090 |
Why?
|
| Sepsis | 1 | 2013 | 233 | 0.090 |
Why?
|
| NF-kappa B | 3 | 2020 | 432 | 0.090 |
Why?
|
| Serogroup | 2 | 2021 | 6 | 0.080 |
Why?
|
| Electrons | 2 | 2007 | 25 | 0.080 |
Why?
|
| Zinc | 2 | 2007 | 73 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 250 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 581 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 438 | 0.080 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2008 | 21 | 0.080 |
Why?
|
| Electrochemistry | 5 | 2007 | 70 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 267 | 0.080 |
Why?
|
| Risk Factors | 3 | 2016 | 5731 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2008 | 183 | 0.070 |
Why?
|
| HIV Infections | 2 | 2012 | 791 | 0.070 |
Why?
|
| Neutrophils | 2 | 2019 | 204 | 0.070 |
Why?
|
| Photosynthetic Reaction Center Complex Proteins | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bromine | 1 | 2006 | 8 | 0.070 |
Why?
|
| Macromolecular Substances | 1 | 2007 | 122 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.070 |
Why?
|
| Fetal Growth Retardation | 1 | 2007 | 56 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 291 | 0.070 |
Why?
|
| Pyrroles | 1 | 2006 | 83 | 0.070 |
Why?
|
| Infant Food | 1 | 2005 | 16 | 0.070 |
Why?
|
| Angiostatins | 1 | 2005 | 3 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 219 | 0.060 |
Why?
|
| Thalidomide | 1 | 2005 | 24 | 0.060 |
Why?
|
| Infant | 2 | 2017 | 2891 | 0.060 |
Why?
|
| Enzymes, Immobilized | 1 | 2005 | 11 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2005 | 75 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 64 | 0.060 |
Why?
|
| Crown Ethers | 1 | 2004 | 1 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2007 | 241 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 191 | 0.060 |
Why?
|
| Virus Replication | 2 | 2017 | 104 | 0.060 |
Why?
|
| Electrodes | 1 | 2005 | 147 | 0.060 |
Why?
|
| Toll-Like Receptors | 2 | 2020 | 56 | 0.060 |
Why?
|
| Molecular Structure | 4 | 2006 | 397 | 0.060 |
Why?
|
| Breast Feeding | 1 | 2005 | 159 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2007 | 631 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2010 | 294 | 0.060 |
Why?
|
| Zinc Compounds | 1 | 2003 | 9 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2021 | 1692 | 0.050 |
Why?
|
| Pepsinogen A | 1 | 2003 | 1 | 0.050 |
Why?
|
| United States | 4 | 2016 | 7367 | 0.050 |
Why?
|
| Hematocrit | 1 | 2003 | 70 | 0.050 |
Why?
|
| Gastrins | 1 | 2003 | 27 | 0.050 |
Why?
|
| Breath Tests | 1 | 2003 | 23 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 39 | 0.050 |
Why?
|
| Biliopancreatic Diversion | 1 | 2002 | 3 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 2002 | 7 | 0.050 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 208 | 0.050 |
Why?
|
| Neoplasms | 1 | 2014 | 1667 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 2002 | 2 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2022 | 94 | 0.050 |
Why?
|
| Aminoquinolines | 1 | 2002 | 14 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 507 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2003 | 95 | 0.050 |
Why?
|
| Creatinine | 1 | 2003 | 243 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 63 | 0.050 |
Why?
|
| Vero Cells | 1 | 2022 | 13 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 44 | 0.050 |
Why?
|
| Metals | 1 | 2022 | 100 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1174 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 50 | 0.050 |
Why?
|
| Receptors, Epoprostenol | 1 | 2021 | 3 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 626 | 0.050 |
Why?
|
| Bacterial Adhesion | 1 | 2021 | 33 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2023 | 170 | 0.050 |
Why?
|
| Male | 7 | 2016 | 37321 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 248 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2013 | 489 | 0.050 |
Why?
|
| Oxygen | 1 | 2022 | 386 | 0.050 |
Why?
|
| Family | 1 | 2023 | 293 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 226 | 0.050 |
Why?
|
| Liver | 2 | 2021 | 1118 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2002 | 172 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 532 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 160 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 370 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 324 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2010 | 1851 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 22 | 0.040 |
Why?
|
| Prostaglandins | 1 | 2019 | 65 | 0.040 |
Why?
|
| Histidine Kinase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2018 | 43 | 0.040 |
Why?
|
| Leucine | 1 | 2018 | 41 | 0.040 |
Why?
|
| Orosomucoid | 1 | 2017 | 5 | 0.040 |
Why?
|
| Tryptophan | 1 | 2018 | 65 | 0.040 |
Why?
|
| Receptors, Transferrin | 1 | 2017 | 18 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 137 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 43 | 0.040 |
Why?
|
| Ferritins | 1 | 2017 | 49 | 0.040 |
Why?
|
| United Nations | 1 | 2017 | 1 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 147 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2008 | 40 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 223 | 0.040 |
Why?
|
| Microbial Viability | 1 | 2017 | 27 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 714 | 0.040 |
Why?
|
| Serotyping | 1 | 2016 | 16 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2016 | 11 | 0.040 |
Why?
|
| Membrane Lipids | 1 | 2016 | 31 | 0.040 |
Why?
|
| Administration, Buccal | 1 | 2016 | 1 | 0.040 |
Why?
|
| Elafin | 1 | 2016 | 1 | 0.040 |
Why?
|
| Mass Screening | 1 | 2003 | 843 | 0.040 |
Why?
|
| Histones | 1 | 2017 | 111 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 11 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 180 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 47 | 0.040 |
Why?
|
| Cell Death | 1 | 2017 | 329 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 2791 | 0.030 |
Why?
|
| Immune System | 1 | 2016 | 63 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2021 | 1330 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 499 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 106 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 291 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 245 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 260 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 175 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2016 | 222 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2016 | 228 | 0.030 |
Why?
|
| Molecular Conformation | 2 | 2007 | 128 | 0.030 |
Why?
|
| Microbiota | 1 | 2016 | 80 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 579 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 86 | 0.030 |
Why?
|
| Palladium | 2 | 2005 | 12 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 786 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2005 | 79 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 35 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 782 | 0.030 |
Why?
|
| Women | 1 | 2014 | 40 | 0.030 |
Why?
|
| Streptococcus pyogenes | 1 | 2013 | 20 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 84 | 0.030 |
Why?
|
| Uterus | 1 | 2013 | 77 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2013 | 14 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 931 | 0.030 |
Why?
|
| Poverty | 1 | 2014 | 219 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 287 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2010 | 1034 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 1342 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2012 | 62 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 742 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 955 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 59 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 156 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 127 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2279 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 132 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 140 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 729 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 786 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 397 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 710 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2010 | 238 | 0.020 |
Why?
|
| Rural Population | 1 | 2011 | 398 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2008 | 137 | 0.020 |
Why?
|
| Embryo Transfer | 1 | 2007 | 18 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2007 | 34 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 947 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 75 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 99 | 0.020 |
Why?
|
| Time Factors | 2 | 2007 | 4655 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 597 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 169 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2006 | 81 | 0.020 |
Why?
|
| Organ Size | 1 | 2007 | 242 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 238 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1753 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 48 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 163 | 0.020 |
Why?
|
| Vanadium | 1 | 2004 | 5 | 0.020 |
Why?
|
| Nickel | 1 | 2004 | 18 | 0.020 |
Why?
|
| Body Weight | 1 | 2007 | 554 | 0.020 |
Why?
|
| Cobalt | 1 | 2004 | 37 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 304 | 0.010 |
Why?
|
| Silver | 1 | 2004 | 49 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 190 | 0.010 |
Why?
|
| Magnesium | 1 | 2004 | 110 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1664 | 0.010 |
Why?
|
| Adsorption | 1 | 2005 | 225 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 183 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 442 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 396 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 567 | 0.010 |
Why?
|
| Electron Transport | 1 | 2003 | 37 | 0.010 |
Why?
|
| Copper | 1 | 2004 | 149 | 0.010 |
Why?
|
| Fluorescence | 1 | 2003 | 104 | 0.010 |
Why?
|
| Receptors, CCR7 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 981 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 16 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2002 | 21 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2002 | 26 | 0.010 |
Why?
|
| Solvents | 1 | 2003 | 109 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2002 | 57 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2002 | 63 | 0.010 |
Why?
|
| Interferon Type I | 1 | 2002 | 32 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 384 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2002 | 46 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 191 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2083 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 124 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2002 | 91 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 546 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2002 | 286 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 1196 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 5300 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 1293 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 14862 | 0.010 |
Why?
|